Trial Profile

An Open Label, Multiple Centers Phase Ib/II Study of APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 16 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs APG 1387 (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
Indications Adenocarcinoma; Pancreatic cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Ascentage Pharma

Most Recent Events

14 Aug 2024 Planned End Date changed from 1 Dec 2024 to 31 Dec 2024.
14 Aug 2024 Planned primary completion date changed from 1 Jun 2024 to 31 Dec 2024.
27 Mar 2024 Planned End Date changed from 1 Jul 2024 to 1 Dec 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com